Why Kezar Life Sciences Stock Is Crushing It Today

·1 min read
Why Kezar Life Sciences Stock Is Crushing It Today

Shares of the clinical-stage biotech Kezar Life Sciences (NASDAQ: KZR) are soaring this morning following a positive mid-stage data readout for its lupus nephritis candidate zetomipzomib. This potentially deadly autoimmune disorder is characterized by swelling of the kidneys in patients with systemic lupus erythematosus. What appears to be driving this massive uptick in Kezar's shares today is the drug's 65% overall renal response among patients who reached the end of treatment.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting